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1. Introduction 
On one occasion, when I served on the UN Committee on Economic, Social and Cultural Rights 
(CESCR), the Committee was provided with a substantive report, prepared by a civil society 
organisation, alleging that a major transnational company was complicit in egregious violations 
of economic, social and cultural rights in a particular low-income country. The report was 
submitted to the Committee as part of its periodic review of the country which was a State party 
to the International Covenant on Economic, Social and Cultural Rights (ICESCR).1 Some 
Committee members took the view that the allegations were so compelling that the Committee 
should endeavour to engage in a respectful discussion, either written or oral, with the company in 
question. Other members argued that such an approach would fall beyond the Committee’s 
competence, after all the transnational company had not, and could not, ratify the Covenant; they 
continued that the Committee should confine itself to asking the State party, during its 
constructive dialogue, about the government’s duty to protect individuals from the depredations 
of corporate third parties. The latter conventional view prevailed and the Committee declined to 
engage with the transnational company in question. 
 
Although the wording of their mandates vary, the UN Human Rights Council’s Special 
Procedures tend to have more scope than human rights treaty-bodies, such as CESCR, to 
consider the acts, omissions and responsibilities of non-state actors. Consider, for example, the 
mandate establishing the special procedure on the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health (‘right to health’). It requests the 
Rapporteur to: ‘gather, request, receive and exchange information from all relevant sources’; 
‘develop a regular dialogue and discuss possible areas of cooperation with all relevant actors, 
including ... international financial institutions’; ‘report on the status of the [right to health] ... 
and on developments relating to this right, including on laws, policies and good practices most 
beneficial to its enjoyment and obstacles encountered domestically and internationally to its 
implementation’; and ‘make recommendations on appropriate measures to promote and  protect 
the realization of the [right to health], with a view to supporting States’ efforts to enhance public 
health’.2 These provisions, with their references to ‘all relevant sources’, ‘all relevant actors’, 
‘good practices’, ‘appropriate measures’ and so on, give scope to the mandate-holder to explore 
the role of non-state actors. In short, it is easier for the mandate-holder to look closely at non-
state actors than it is for CESCR. 
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January 1976) 993 UNTS 3 (ICESCR). 
2 United Nations Committee on Economic, Social and Cultural Rights ‘General Comment 14’ (22 April 2000), UN 
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When I served as Rapporteur on the right to health (2002-8), Ministers of Health and others 
convincingly argued that among the obstacles to their implementation of health rights were the 
policies and practices of non-state actors. These views were expressed, for example, in 
interviews conducted during missions. In these circumstances, I formed the view that, given the 
wording of my mandate, it would have been a dereliction of duty not to explore the role of non-
state actors. Of course, I was alert to the possibility that governments might point to non-state 
actors as a way of excusing or masking their own shortcomings. Throughout the mandate, my 
primary focus was States and my main task was to hold them accountable. Nonetheless, from 
time to time, I also considered non-state actors. 
 
This chapter does not aim to examine the substance of my right-to-health reports on non-state 
actors, such as the World Trade Organisation (WTO), World Bank, International Monetary Fund 
(IMF), and GlaxoSmithKline (GSK) - this has already been done in a number of different 
publications.3 For the first time, however, the chapter brings together in one place, and reflects 
upon, several of my more significant experiences with non-state actors while I was Special 
Rapporteur. 
 
Before proceeding, I would like to signal some important doctrinal matters. I agree with Michael 
Freeman’s observation that ‘the concept of human rights is centrally concerned with the misuse 
of power’.4 In its statement on poverty in 2001, CESCR takes a similar position: ‘Although 
human rights are not a panacea, they can help to equalize the distribution and exercise of power 
within and between societies.’5 However, the contemporary concept of international human 
rights is more narrowly drawn: its focus is neither power, nor even public power, in general. The 
contemporary concept of international human rights is intended ‘primarily to protect individuals 
from the abuse of power by governments’.6 This preoccupation with individuals as rights-holders 
and governments as duty-bearers reflects the main concerns of the architects of the International 
Bill of Rights in the shadow of the Second World War. Many of them had witnessed the 
persecution of individuals by deeply oppressive State power. Understandably, they toiled to 
negotiate an international code of conduct that would protect individuals from abusive States. In 
my view, however, there is no compelling reason why the concept of human rights cannot 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 See eg P Hunt and S Leader, ‘Developing and applying the right to the highest attainable standard of health: the 
role of the UN Special Rapporteur’ in J Harrington and M Stuttaford (eds), Global Health and Human Rights: 
Philosophical and Legal Perspectives ((Routledge 2010); P Hunt and S Walker, ‘WTO member states and the right 
to health’ in J Dine and A Fagan (eds), Human Rights and Capitalism (Edward Elgar Publishing 2006); P Hunt, J 
Mesquita and R Khosla, ‘The human rights responsibility of international assistance and cooperation in health’ in M 
Gibney and S Skogly (eds), Universal Human Rights and Extraterritorial Obligations (Pennsylvania Studies in 
Human Rights 2010); J-Y Lee and P Hunt, ‘Human rights responsibilities of pharmaceutical companies in relation to 
access to medicines’ (2012) Journal of Law, Medicine and Ethics 220; P Hunt and R Khosla, ‘Holding 
pharmaceutical companies to account: a UN Special Rapporteur’s mission to GlaxoSmithKline’ in G Gilbert, F 
Hampson and C Sandoval (eds), The Delivery of Human Rights: Essays in Honour of Professor Sir Nigel Rodley 
(Routledge 2010); P Hunt and R Khosla, ‘The human right to medicines’ (2008) Sur: International Journal on 
Human Rights 98. 
4 Emphasis in original. M Freeman, Human Rights (2nd edn, Polity Press 2011) 210. 
5 UN CESCR ‘Substantive Issues Arising in the Implementation of the International Covenant on Economic, Social 
and Cultural Rights: Poverty and the International Covenant on Economic, Social and Cultural Rights’ (10 May 
2001), UN Doc E/C.12/2001/10. 
6 Freeman (n 4) 16. 
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encompass groups of individuals as rights-holders and powerful non-state actors as duty-bearers. 
Of course, contemporary international human rights are designed to hold States accountable and 
it would be facile simply to apply these standards to non-state actors. For example, although 
ICESCR includes an obligation to adopt ‘legislative measures’, it would be absurd to suggest 
that transnational corporations should have legislative powers.7 Plainly, normative adjustments 
are needed if human rights obligations are to extend to powerful non-state actors. While it is not 
the purpose of this chapter to examine the doctrinal dimensions of these issues, in my view the 
concept of human rights is impoverished if it is confined to the misuse of State power.8 We have 
to find suitable ways -- new thinking and practice -- to extend human rights accountability to 
powerful non-state actors. This is what animated my exploratory initiatives as briefly outlined in 
this chapter. 
 
After these introductory remarks, this chapter looks at non-state actors in relation to the three 
types of reports I submitted to the United Nations. First, I consider two thematic reports on the 
pharmaceutical sector, including a report submitted to the General Assembly setting out Human 
Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines. Second, I 
discuss ‘country’ reports which I used as a vehicle for looking at non-state actors, such as the 
WTO, World Bank, IMF and GSK. Third, I introduce my reports on complaints (or 
‘communications’ to use the language of the United Nations) about alleged violations of the right 
to health that were brought to my attention when the allegations were unconnected with a 
country visit; these reports include complaints against two non-state actors. The chapter ends 
with a brief conclusion. 
 
2. Thematic reports 
Like other special procedures, when preparing thematic reports, I always consulted with non-
state actors, such as UN agencies and civil society.9 Additionally, the thematic reports often 
considered the roles of non-state actors in relation to the right to health issues that were the 
subject of the reports.10 However, because of the strict word limits placed on these reports, their 
treatment of non-state actors was often superficial. I formed the view that I could not depend 
upon these usual methodological approaches when looking at the pharmaceutical sector which 
plays such a critically important role in relation to one vital component of the right to health: 
access to medicines. On numerous occasions, ministers, senior public officials, civil society and 
others complained that the policies of some pharmaceutical companies, including their 
excessively high prices for medicines, were an obstacle to the national implementation of the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 International Covenant on Economic, Social and Cultural Rights (adopted 16 December 1966, entered into force 3 
January 1976) 993 UNTS 3 (ICESCR), Art 2(1). 
8	  Among the relevant literature is A Clapham, Human Rights Obligations of Non-State Actors (OUP 2006); N 
Rodley, ‘Non State Actors and Human Rights’ in S Sheeran and N Rodley (eds), Routledge Handbook of 
International Human Rights Law (Routledge 2013); P Alston, ‘The “Not-a-Cat” Syndrome: Can the International 
Human Rights Regime Accommodate Non-State Actors?’, in P Alston (ed), Non-State Actors and Human Rights 
(OUP 2005). 
9	  See, for example, UN Commission on Human Rights (UNCHR) ‘The right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health: Report of the Special Rapporteur, Paul Hunt’ (13 February 
2003) UN Doc E/CN.4/2003/58, paragraphs 3-7. 
10	  See, for example, UNCHR ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health, Paul Hunt’ (11 February 2005) UN Doc E/CN.4/2005/51, 
paragraph 49. 
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right to health. Accordingly, I devised three ways of addressing the human rights responsibilities 
of pharmaceutical companies: first, in a thematic report on access to medicines that includes 
sections on the responsibilities of States and pharmaceutical companies;11 second, in a thematic 
report that presented Human Rights Guidelines for Pharmaceutical Companies in relation to 
Access to Medicines to the General Assembly;12 and third, in a formal mission to GSK.13  I 
briefly comment on the two thematic reports in this section and introduce the GSK report in the 
next. 
 
My thematic report to the General Assembly in 2006 underlined that there is a human right to 
medicines and explored its different dimensions, such as access, quality, participation and 
accountability.14 It emphasised that states have primary responsibility to increase access to 
medicines but underscored that Millennium Development Goal 8 confirms this is a shared 
responsibility and pharmaceutical companies are among those with some responsibility.15 The 
report argued that a consensus is emerging that business enterprises have some legal and ethical 
human rights responsibilities and it introduces draft Guidelines on the scope and content of the 
responsibilities of pharmaceutical companies in relation to access to medicines.16 The report 
encouraged all parties to submit comments on the draft Guidelines.17 
 
My last report to the General Assembly in 2008 presented the finalised Human Rights Guidelines 
for Pharmaceutical Companies in relation to Access to Medicines, which consist of a preamble, 
47 guidelines and a commentary.18 The Guidelines are detailed, specific and practical. They 
address a wide range of issues including transparency, corruption, lobbying, clinical trials, 
patents, licensing, pricing and accountability. The report explains the lengthy consultative 
process from which the Guidelines emerged.19 I will not set out this process here but note three 
features of it. First, stretching over some five years, the process included many discussions and 
workshops with the pharmaceutical sector. Second, civil society played a very significant part. 
Third, for much of this process, leadership was provided by former High Commissioner for 
Human Rights, Mary Robinson, President of Realizing Rights: The Ethical Globalization 
Initiative (EGI). The contributions of Mary Robinson and her EGI colleagues were 
indispensable. 
 
The effective promotion and protection of human rights requires a keen sense of strategy. In the 
context under discussion, I made a strategic calculation which requires brief explanation. As 
reported to the General Assembly in 2006, the key issues in relation to the pharmaceutical sector 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11	  UN General Assembly (UNGA) ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of 
the highest attainable standard of physical and mental health, Paul Hunt’ (13 September 2006) UN Doc	  A/61/338.	  
12	  UNGA ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable 
standard of physical and mental health, Paul Hunt’ (11 August 2008) UN Doc A/63/263.	  
13	  UNGA ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable 
standard of physical and mental health, Paul Hunt – Mission to GlaxoSmithKline’ (5 May 2009) UN Doc 
A/HRC/11/12/Add.2. 
14 UNGA (n 11). 
15	  ibid, paragraph 82. 
16	  ibid, paragraphs 90 and 92. 
17	  ibid, paragraph 91. 
18 UNGA (n 12) section IV and annex. 
19 ibid, section IV. 
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and human rights include, first, clarifying the scope and content of the sector’s human rights 
responsibilities, and second, identifying which are legal and which are ethical responsibilities.20 
In my view, discussion within the human rights community usually focussed on the second issue 
and neglected the first, and this led to a complaint from some pharmaceutical companies that, 
while they were willing to comply with the right to health, nobody could explain to them the 
contours and content of their right to health responsibilities. Thus, I made a strategic decision 
temporarily to put aside the second issue and to focus on the first. 
 
Accordingly, as reported to the General Assembly in 2008, Mary Robinson and I proposed a 
collaborative project with some pharmaceutical companies with a view to identifying the right to 
health responsibilities of the pharmaceutical sector; regrettably, the companies’ response to our 
proposal was insufficient for the project to proceed.21 Undaunted, I prepared Guidelines that 
demonstrate, in some detail, how international human rights norms apply to pharmaceutical 
companies in relation to access to medicines. Importantly, my focus on clarifying the scope and 
content of pharmaceutical companies’ human rights responsibilities, rather than identifying 
which are legal and which are ethical, should not be interpreted as meaning that, in my view, 
international human rights norms place no legally binding obligations on pharmaceutical 
companies. On the contrary, as I emphasise in the 2006 report, ‘it is inconceivable that some 
human rights do not place legal responsibilities on business enterprises’.22 Identifying which 
responsibilities of pharmaceutical companies in relation to access to medicines are legal, and 
which are ethical, is an important but different exercise. 
 
3. ‘Country’ reports 
My first report to the UN Commission on Human Rights in 2003 identified my priorities as 
mandate-holder, one of which was to consider the WTO.23 I thought it would send a suitable 
message if my first ‘country’ report was on WTO. Conscious this would be the first of its kind, I 
informally discussed the idea with the High Commissioner for Human Rights, Sergio de Mello. 
While leaving the decision to me, the High Commissioner encouraged me to proceed. After I had 
decided to go ahead, it was agreed that the High Commissioner would take the unusual step of 
writing to the Director-General of WTO, Supachai Panitchpakdi, proposing that I visit.24 The 
Director-General replied positively and, in due course, an intense seven-day schedule of 
meetings with WTO members, WTO secretariat and many others, took place.25 One of the 
mission’s aims was to highlight the problem of disconnected government, ie one part of 
government (trade) does not necessarily grasp what another part of the same government (justice 
and foreign affairs) has agreed to do. The mission also sought to highlight disconnect between 
international bodies, for example, WTO and OHCHR. Thus, the mission alerted the WTO 
secretariat to the health rights dimensions of their work. Published in 2004, the mission report 
addressed these, and a range of complex trade issues, through a right to health ‘lens’.26 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
20 UNGA (n 11) paragraph 93. 
21 UNGA (n 12), section IV. 
22 UNGA (n 11), para 93. 
23 UNCHR (n 9). 
24 UNCHR ‘The right of everyone to the enjoyment of the highest attainable standard of physical and mental health: 
report of the Special Rapporteur, Paul Hunt – Mission to the World Trade Organization’ (1 March 2004) UN Doc 
E/CN.4/2004/49/Add.1, paragraph 2, 
25	  ibid, Introduction.	  
26 ibid. 
6	  
	  
 
My second report on Sweden looked at analogous issues but this time in relation to the World 
Bank and IMF. In January 2006, I was invited to Sweden to prepare a report on how the 
Government was domestically implementing the right to health.27 Subsequently, I informed the 
Government that I was interested in preparing a second report, this time on the implementation 
of Sweden’s international policies so far as they bear upon the right to health. To its credit, the 
Government agreed to cooperate. This second report was a way of exploring Sweden’s extra-
territorial human rights obligations, analysing the meaning and application of ‘international 
assistance and cooperation’ as set out in article 2(1) ICESCR, and taking health rights into the 
halls and corridors of the World Bank and IMF. Thus, in October 2006 I visited Washington DC 
and discussed with the Executive Directors of the Nordic-Baltic countries in the World Bank and 
IMF (ie, the representatives of Sweden in the Bank and IMF) how they sought to take account of 
Sweden’s international human rights policies in their work. In February 2007, at the invitation of 
Uganda, I visited Kampala to examine how Sweden, especially the Swedish International 
Development Cooperation Agency, contributes to the realisation of the right to health in Uganda. 
I also wished to explore Sweden’s role in Zambia’s health sector but did not receive Lusaka’s 
permission to visit, accordingly my report does not include Zambia. The report made numerous 
recommendations for Sweden and its representatives in the World Bank, the IMF and Uganda. 
Some of the report has general application, such as the section outlining the human rights 
responsibility of international assistance and cooperation in health.28 The points made in this 
section are not only relevant to Sweden, but all donors, as well as members of the World Bank 
and IMF. Additionally, the report addressed some of the institutional barriers to the 
operationalisation of health rights within the Bank and Fund.29 
 
Throughout my mandate, I regularly scrutinised States’ duties and practice in relation to access 
to medicines. As already discussed, I began to look closely at the responsibilities of the 
pharmaceutical sector in relation to access to medicines and devised three ways of advancing this 
agenda, two of which I have signalled in the preceding section. The third initiative was to 
conduct a formal mission to GSK. Before proceeding, however, I took two steps. First, given the 
unprecedented nature of the proposed mission, I informally consulted Gay McDougall, Chair of 
the Coordination Committee of Special Procedures of the UN Human Rights Council, who 
indicated that, while it was entirely a matter for me, the mission had her support. Second, 
pharmaceutical companies and access to medicines raise technical issues and so I hired a 
consultant, with many years of experience of the pharmaceutical sector, to provide some 
technical advice. I chose GSK because it is one of the world’s leading research-based 
pharmaceutical companies. GSK confirmed their agreement to the mission and months of 
research began. Many meetings took place, including with the highest levels of management in 
GSK’s headquarters, as well as civil society organisations working on access to medicines. 
Effectively, the GSK report drew from, and applied, the Human Rights Guidelines for 
Pharmaceutical Companies in relation to Access to Medicines.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
27 UN Human Rights Council (UNHRC) ‘Report of the Special Rapporteur on the right of everyone to the 
enjoyment of the highest attainable standard of physical and mental health, Paul Hunt – Mission to Sweden’ (28 
February 2007) UN Doc A/HRC/4/28/Add.2. 
28 UNHRC ‘Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable 
standard of physical and mental health, Paul Hunt – Missions to the World Bank and the International Monetary 
Fund in Washington, D.C. and Uganda’ (5 March 2008) UN Doc A/HRC/7/11/Add.2, Section II. 
29 ibid, section V, B. 
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From the perspective of the right to health, the report critiques some GSK policies on access to 
medicines, especially in relation to developing countries, and makes numerous recommendations 
for GSK, States and others.30 The report was formally presented to the UN Human Rights 
Council in June 2009 by my successor Anand Grover. I tried to ensure that GSK could orally 
respond to the report from the floor of the Council, just as a State is able to respond to a report on 
itself. Although GSK wished to speak, and a senior company representative was present in the 
Council at the relevant time, permission was not granted by the President of the Council. This 
was regrettable and inconsistent with well-established principles of procedural fairness. 
However, the President publicly referred to GSK’s written response, which was circulated in the 
Council. The GSK report generated considerable interest. For example, the UK delegate made an 
oral statement thanking both GSK and the author, and said ‘businesses should ... ensure that they 
conduct their activities in a manner that is consistent with enjoyment of human rights’.31 In an 
article headed ‘Right-to-health responsibilities of pharmaceutical companies’, the Lancet 
published an editorial on the GSK report and Guidelines: ‘Pharmaceutical companies help 
deliver the right to health. They save lives. But with this role comes responsibilities – and 
companies must be better held to account in relation to those responsibilities. The 2008 
guidelines and the GSK report move us closer to that goal.’32 My focus in this section has been 
on the missions to the WTO, the World Bank and the IMF, and GSK. However, during more 
orthodox country-focused missions I also engaged with international financial institutions and 
pharmaceutical companies. For example, when visiting Mozambique I discussed relevant health 
rights issues with the World Bank in Maputo,33 and when preparing a report on neglected 
diseases in Uganda I met with local representatives of pharmaceutical companies in Kampala.34 
Sometimes my interlocutors in these meetings were mystified by my interest and questions. But 
the main point of engaging with them was to convey that the work of their institutions was 
intimately connected with international health rights. 
 
4. Complaints 
Although the right to health mandate does not explicitly include the receipt of complaints, I took 
up some of the alleged violations that were brought to my attention by individuals and 
organisations even when the allegations were unconnected with a country visit. Four annual 
reports summarising these communications were submitted to either the Commission on Human 
Rights or Human Rights Council.35	   While the bulk of these complaints were against 
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  UNGA (n 13), sections IV and V. 
31 Hunt and Khosla (n 3) 67. 
32 Editorial, ‘Right-to-health responsibilities of pharmaceutical companies’ (13 June 2009) 373(9680) The Lancet 
1998 
<	  http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(09)61090-4.pdf> accessed 22 October 2015. 
33 UNCHR ‘The right of everyone to the highest attainable standard of physical and mental health: Report of the 
Special Rapporteur, Paul Hunt. Addendum - Mission to Mozambique’ (4 january 2005), UN Doc 
E/CN.4/2005/51/Add.2. 
34 UNCHR ‘Report of the Special Rapporteur on the right of everyone to the highest attainable standard of physical 
and mental health, Paul Hunt: Addendum – Mission to Uganda’ (19 January 2006) UN Doc E/CN.4/2006/48/Add.2. 
35 UNCHR ‘Report of the Special Rapporteur on the right of everyone to the highest attainable standard of physical 
and mental health, Paul Hunt: Addendum – Summary of cases transmitted to Governments and replies received’ (2 
February 2005) UN Doc E/CN.4/2005/51/Add.1; UNCHR ‘Report of the Special Rapporteur on the right of 
everyone to the highest attainable standard of physical and mental health, Paul Hunt: Addendum – Summary of 
communications sent to and replies received from Governments and other actors, December 2004-December 2005’ 
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governments, communications were also sent to the UN Interim Administration Mission to 
Kosovo (UNMIK), as well as the Global Fund to Fight AIDS, Tuberculosis and Malaria. In 
2005, an urgent appeal to UNMIK, with two other Rapporteurs, concerned the relocation of 
internally displaced persons affected by severe lead contamination in camps in northern Kosovo; 
a constructive correspondence continued until 2007.36 In 2005, a letter to the Global Fund 
expressed concern about the Fund’s decision to terminate grants to Myanmar and an 
inconclusive correspondence continued into 2006.37 The title of the annual reports on 
communications changed from Summary of cases transmitted to Governments and replies 
received (2005) to Summary of communications sent to and replies received from Governments 
and other actors (2008, emphasis added). 
 
5. Conclusion 
While States occupied the bulk of my time as mandate holder, exploring the role of non-state 
actors was a recurrent theme occupying about 10 per cent of my capacity as Rapporteur. Nobody 
tried to dissuade me from looking at non-state actors. High-income countries tended to be more 
diffident than low- or middle-income countries. Reaction within the World Bank, IMF and WTO 
to this dimension of my work was patchy, ranging from enthusiasm to confusion. With regard to 
pharmaceutical companies, some that I engaged with were very well-informed and constructive; 
others were going through the motions. Moreover, I always had the sense that my engagement 
with them was something they wished to control. There was a degree of nervousness among 
some (not all) OHCHR staff, but they were unfailingly supportive, professional and very hard-
working. The support provided by High Commissioner Sergio de Mello, and the collaborative 
leadership provided by former High Commissioner Mary Robinson was extremely important. On 
the whole, civil society was enthusiastic, although some worried I would ‘sell-out’ and others 
were concerned that I would go too far. 
 
Of course, I never expected the WTO, World Bank and IMF suddenly to mainstream health 
rights into their work, and I knew it was unlikely that pharmaceutical companies would embrace 
the Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines. 
My aims were to expose disconnected government, to signal how health rights mainstreaming 
could occur in the WTO, World Bank and IMF, to show that it was possible to apply human 
rights norms - with a considerable degree of operational specificity - to pharmaceutical 
companies in relation to access to medicines, and to demonstrate that GSK, one of the world’s 
largest pharmaceutical companies, could be held accountable by a UN human rights mechanism. 
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cases transmitted to Governments and replies received’ (23 February 2007) UN Doc A/HRC/4/28/Add.1; UNHRC 
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  UNCHR ‘Report of the Special Rapporteur on the right of everyone to the highest attainable standard of physical 
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E/CN.4/2006/48/Add.1, paragraphs 78-80; UNHRC ‘Report of the Special Rapporteur on the right of everyone to 
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In the Introduction, I observe that international human rights were primarily designed, in the 
years following the Second World War, to protect individuals from the abuse of power by 
governments. For this reason, it was more challenging to give serious thought to the possibility 
of extending human rights accountability to non-state actors, than it was to actually undertake the 
initiatives outlined in this chapter. In the long term, perhaps the most significant feature of these 
initiatives is that they took place at all. 
 
